|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.06.26 - 12:42
|
Sweden Passes Law To Revoke Residence Permits From Migrants Who Fail ′Good-Behavior′ Test (ZeroHedge)
|
|
|
Sweden Passes Law To Revoke Residence Permits From Migrants Who Fail 'Good-Behavior' Test
Via Remix News,
Sweden has passed a new migration law that will allow residence permits to be refused or revoked if foreign nationals are deemed not to have lived in an orderly manner, marking another major tightening of the country's immigration system.
The Swedish Parliament adopted the government's amendments to existing immigration laws on Monday by 302 votes to 44, with the Left Party and the Green Party voting against the measure. The changes will mainly come into force next month.
Under the new rules, a foreign national's conduct will carry greater weight when authorities decide whether to grant, extend, or revoke a residence permit. The law does not set out an exhaustive list of behaviors that will be treated as unacceptable, leaving the Migration Agency to assess cases individually. It means that an immigrant who may not hold a criminal record but has acted in a disorderly manner in other wa...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.06.26 - 19:48
|
Genova initiates share buy-back programme (Cision)
|
|
|
At the Annual General Meeting of Genova Property Group AB (publ) ("Genova" or the "Company") held on 6 May 2026, the Board was authorised to, during the period until the next Annual General Meeting, resolve on repurchase of the Company's own ordinary shares. The Board of the Company has today decided to exercise the authorisation and initiate a share buy-back programme of own ordinary shares. The repurchases will continue until the Annual General Meeting of 2027 at the latest.
Terms and conditions for repurchase of own ordinary shares
According to the Board's decision, the Company's...
|
|
|
|
|
18.06.26 - 17:54
|
EQT exits remaining stake in Beijer Ref (PR Newswire)
|
|
|
STOCKHOLM, June 18, 2026 /PRNewswire/ -- EQT completes final selldown of shares in Beijer Ref, a globally leading wholesaler and distributor of refrigeration, heating, ventilation, and air conditioning (HVAC) technology Under EQT's ownership, Beijer Ref has more than doubled revenues and......
|
|
|
18.06.26 - 16:00
|
Bulletin from Annual General Meeting in Irisity AB (publ) (Cision)
|
|
|
The following resolutions were passed at the annual general meeting of Irisity AB (publ) held today on
18 June 2026 in Gothenburg, Sweden.
Adoption of income statement and balance sheet for the financial year 2025 and discharge from liability
The annual general meeting resolved to adopt the income statements and the balance sheets for the company and the group for the financial year 2025. The members of the board of directors and the
CEOs, respectively, were discharged from liability for the financial year 2025.
Allocation of profits
The annual general meeting resolved...
|
|
|
18.06.26 - 15:42
|
BoMill launches APC for increased efficiency (Cision)
|
|
|
BoMill announces the launch of APC – Adaptive Protein Control, an add-on module based on near-infrared (NIR) technology enabling higher efficiency, real-time insights and validated protein content. With the modular design, the APC integrates seamlessly with BoMill InSight™.
Homogeneous products for increased value and efficiency
With its user-friendliness, the APC automatically adjusts according to desired protein content, improving sorting accuracy and providing valuable data insights. The automation reduces the need for manual protein analyses, minimizes the risk of human error...
|
|
|
18.06.26 - 15:24
|
Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma (Cision)
|
|
|
Gothenburg, June 18, 2026 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company's commercially available platform iTANK,announces that the company held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company's iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.
During the meeting, Elicera...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
